Aaron Ciechanover (/ɑːhəˈroʊntʃiˈhɑːnoʊvɛər/ⓘAH-hə-ROHN chee-HAH-noh-vair; Hebrew: אהרן צ'חנובר; born October 1, 1947) is an Israeli biologist who won the Nobel Prize in Chemistry for characterizing the method that cells use to degrade and recycle proteins using ubiquitin.
Aaron Ciechanover
Ciechanover speaking at the Technion, Israel, February 2018
Ciechanover was born in Haifa, British Mandate of Palestine on 1 October 1947[1] into a Jewish family.[2] He is the son of Bluma (Lubashevsky), a teacher of English, and Yitzhak Ciechanover, an office worker.[citation needed] His mother and father supported the Zionist movement and immigrated to Israel from Poland in the 1920s.
Ciehanover, A., Hod, Y. and Hershko, A. (1978). A Heat-stable Polypeptide Component of an ATP-dependent Proteolytic System from Reticulocytes. Biochem. Biophys. Res. Commun. 81, 1100–1105. (His name was wrongly transliterated from Hebrew in this publication.)
Ciechanover, A., Heller, H., Elias, S., Haas, A.L. and Hershko, A. (1980). ATP-dependent Conjugation of Reticulocyte Proteins with the Polypeptide Required for Protein Degradation. Proc. Natl. Acad. Sci. USA 77, 1365–1368.
Hershko, A. and Ciechanover, A. (1982). Mechanisms of intracellular protein breakdown. Annu. Rev. Biochem. 51, 335–364.
Hershko, A. and Ciechanover, A. (1998). THE UBIQUITIN SYSTEM. Biochem. 1998 67:1, 425–479
Ciechanover was an invited guest lecturer at the Yerevan State Medical University in Armenia in 2010.
He lectured at the Pyongyang University of Science and Technology in North Korea in May 2016.
Industry involvementedit
Ciechanover has served on the scientific advisory boards of the following companies: Rosetta Genomics (Chairman), BioLineRx, Ltd, StemRad, Ltd, Allosterix Ltd, Proteologics, Inc, MultiGene Vascular Systems, Ltd, Protalix BioTherapeutics, BioTheryX, Inc., and Haplogen, GmbH.[5]
Ciechanover is a member of the advisory board of Patient Innovation, a nonprofit, international, multilingual, free venue for patients and caregivers of any disease to share their innovations.
In 2004, he was awarded the Nobel Prize in Chemistry for his discovery with Avram Hershko and Irwin Rose, of ubiquitin-mediated protein degradation.[8][9] The ubiquitin-proteasome pathway has a critical role in maintaining the homeostasis of cells and is believed to be involved in the development and progression of cancer, muscular and neurological diseases, and immune and inflammatory responses.
^"Sir Hans Krebs Medal to Harald Stenmark". Oslo University Hospital. Retrieved 16 December 2014.
^"NCKU honors world class scientists, 2008". Archived from the original on 2020-07-27. Retrieved 2020-05-26.
^"Welcome to The University of Cambodia (UC)". uc.edu.kh. Retrieved 2018-05-09.
^"Humboldt-Forschungspreis für Nobelpreisträger Aaron Ciechanover". Retrieved 14 Feb 2023.
^"Aaron Ciechanover". German Academy of Sciences Leopoldina. Retrieved 26 May 2021.
External linksedit
Wikimedia Commons has media related to Aaron Ciechanover.
Scholia has an author profile for Aaron Ciechanover.
Aaron Ciechanover on Nobelprize.org including the Nobel Lecture on December 8, 2004 Intracellular Protein Degradation: From a Vague Idea thru the Lysosome and the Ubiquitin-Proteasome System and onto Human Diseases and Drug Targeting